The trajectory of companies tied to the drug's legacy presents a challenging investment landscape. While the initial boom generated substantial profits , generic copies have significantly eroded revenue. Investing in connected pharmaceutical companies now requires a thorough assessment of intellectual property rights , evolving medical trends , and